
ASPI Stock Forecast & Price Target
ASPI Analyst Ratings
Bulls say
ASP Isotopes is a progressive company with successful revenue streams and future growth plans, including entry into the global radiopharmaceutical and nuclear fuel markets. Their subsidiary, PET Labs, is facing production delays, but a potential spin-off of Quantum Leap Energy and expansion into Iceland and human trials for cancer treatment show promising opportunities. Although the CEO's medical condition may impact travel plans, the company is well-positioned for continued success in the future.
Bears say
ASP Isotopes is a relatively new company, incorporated in 2021, that is still in the development stage and is focused on scaling production and commercializing its proprietary isotope enrichment technologies. Despite its unique technological advantages and strategic partnerships, the company is facing challenges with management changes and uncertainties surrounding its Phase 2 helium project, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of ASP Isotopes Inc and is not a guaranteed prediction by Public.com or investment advice.
ASPI Analyst Forecast & Price Prediction
Start investing in ASPI
Order type
Buy in
Order amount
Est. shares
0 shares